Katsuaki Maehara, Director of Medical Education Colleagues, shared a post on X about a recent article by Zidong Ma et al, published in BMJ Journal:
“Large-scale analysis examining cardiovascular AEs associated with EGFR-TKIs administration.
Key findings extracted and presented in a graph.
Odds ratio for all cardiac events comparing placebo with EGFR-TKIs monotherapy.
Odds ratio for cardiac events in combination therapy.
EGFR-TKIS use carries a higher risk of cardiovascular AEs than placebo.
With particular caution required for 3rd generation TKIs, whose risk increases when combined with anti-VEGF agents.”
Title: Cardiovascular adverse events associated with epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: systematic review and network meta-analysis
Authors: Zidong Ma, Fei Cao, Mingjuan Liao, Rui Min, Rui Zheng, Xiaolin Sun, Xinlin Chen, Yabin Gong, Sizhi Ai, Xiaohong Kang
Read the Full Article on BMJ Journal
More posts featuring Katsuaki Maehara.